Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rocatinlimab Vaccine Response in Atopic Dermatitis
NCT05899816Phase 3Completed
- Sponsor
- Amgen
- Start
- Jun 2023
- Primary completion
- Aug 2024
- Modality
- Monoclonal Antibodies
- Countries
- 2
01
Overview
Phase 3, randomised, double-blind trial in atopic dermatitis (AD) comparing Rocatinlimab with Placebo (2 arms). Primary endpoints: Percentage of Participants With a Positive Anti-tetanus Response at 24 weeks and Percentage of Participants With a Positive Anti-meningococcal Response at 24 weeks. Started Jun 2023; status: completed.
02
Drugs
rocatinlimab
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT05899816.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05899816.